 Home > Active Ingredient News > Blood System > J Clin Oncol: Ixazomib + subcutaneous injection of rituximab + dexamethasone can effectively treat relapsed or refractory macroglobulinemia!

J Clin Oncol: Ixazomib + subcutaneous injection of rituximab + dexamethasone can effectively treat relapsed or refractory macroglobulinemia!

 Last Update: 2021-08-26
 Source: Internet
 Author: User

Tags

blood sugar levels

what centimeter mean

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Proteasome inhibitors are effective against Waldenström's macroglobulinemia (WM), but require intravenous administration and are associated with polyneuropathy
.

The study investigated the efficacy and toxicity of the less neurotoxic oral proteasome inhibitor Ixazomib combined with rituximab in the treatment of patients with recurrent WM

This is a multicenter Phase 1/2 clinical trial that treats WM patients with ixazomib, rituximab, and dexamethasone (IRD)
.

The induction program includes 8 courses of IRD, of which rituximab is given from the third course of treatment, followed by rituximab for maintenance

A total of 59 patients (average 69 years; range 46-91 years) were recruited
.

The median number of previous treatments was 2 (range 1-17); 70% of patients had a medium to high WH-IPSS (WH International Prognostic Scoring System) score

Mean hemoglobin and hematocrit before eight cycles of treatment-induced immune changes in levels of immunoglobulin M

8 courses before the course of treatment-induced mean hemoglobin and hematocrit immune changes immunoglobulin M levels of immunity

The median duration of remission was 36 months
.

After induction therapy, the average hematocrit of the tested patients increased significantly (0.

After induction therapy, the average hematocrit of the test patient increased significantly.

PFS and OS in intention-to-treat analysis

The median time before the first remission was 4 months
.

The median progression-free survival and overall survival were not reached

After a median follow-up of 24 months (range 7.

Infect

In summary, the combined application of IRD has shown good efficacy and controllable toxicity in patients with relapsed or refractory WM

The combined application of IRD has shown good efficacy and controllable toxicity in patients with relapsed or refractory WM.

Original source:

Marie José Kersten, et al.

Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I / II HOVON124 / ECWM-R2 Study in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.